Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.
Circulating platelets are abundant sources of angiogensis molecules for the tumor vasculature affecting tumor growth and metastasis. The relationship between non-small cell lung cancer (NSCLC) and intra-platelet levels of VEGF, TSP-1 and net platelet angiogenic activity (NPAA) is unclear. The aim of this study was to better understand the role of these factors in the progression of NSCLC cancer and to assess its clinical significance. Platelet VEGF and TSP-1 and NPAA were measured preoperatively in 68 patients with NSCLC by ELISA or Capillary tube formation assay. VEGF, TSP-1 and NPAA distributions in cancer patients and healthy volunteers were compared using the Mann-Whitney U test. The Kaplan-Meier method, univariate and multivariate regression analysis was used to analyze the correlation between these factors and clinicopathological features, overall survival and disease-free survival. Mean intra-platelet TSP-1 level was slightly higher in patients than in healthy subjects (p = 0.092). Intra-platelet TSP-1 levels were significantly higher in patients with involvement greater than T2 or stage III, compared to other patients. Mean intra-platelet VEGF level was 40.8 pg/10⁶ in patients compared to 21.9 ng/10⁶ in healthy subjects (p = 0.041). Median value of NPAA in patients was significantly higher than that in healthy controls (p<0.001). Patients with high NPAA are more likely to exhibit aggressive clinical pathological features. NPAA greater than the median are associated with poor prognosis. The elevated NPAA have better correlation with tumor microvessel density (MVD) than platelet-derived VEGF. The areas under receiver operating curve (AUROC) of NPAA were higher than that of platelet derived VEGF in different groups. A multivariate analysis showed that NPAA are independent prognostic factors. These results indicated that NPAA may be a clinically useful indicator for diagnostic and prognostic evaluation in NSCLC patients.
Department of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
Lijuan
L
Yao
Department of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
Hang
H
Dong
Department of Laboratory Medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
Yiqin
Y
Luo
The Center of Tumor Therapy, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
Jianping
J
Du
Department of Pathology, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
Wen
W
Hu
D000368:Aged; D001792:Blood Platelets / Q000473:pathology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000175:diagnosis / Q000473:pathology*; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D008168:Lung / Q000098:blood supply / Q000473:pathology*; D008175:Lung Neoplasms / Q000098:blood supply* / Q000175:diagnosis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000473:pathology*; D019700:Thrombospondin 1 / Q000032:analysis; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
D019700:Thrombospondin 1; D042461:Vascular Endothelial Growth Factor A